Form 4: OPKO Health Executive Granted 437,500 Stock Options

Steven D. Rubin, Executive VP-Administration and Director at OPKO Health, Inc., was granted 437,500 stock options with an exercise price of $1.31, vesting over four years.

Summary

• Steven D. Rubin, Executive VP-Administration and Director of OPKO HEALTH, INC., was granted 437,500 stock options.
• The options have an exercise price of $1.31 per share.
• The transaction date for this grant was May 27, 2025.
• These options will vest in four equal annual installments, with the first vesting occurring on May 27, 2026.
• The expiration date for these stock options is May 26, 2035.
• Following this transaction, Steven D. Rubin beneficially owns 437,500 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options is a standard and positive incentive for an executive, aligning their interests with shareholders. It does not indicate any negative operational or financial news for the company itself, but rather a routine compensation event.

Positives

• The grant of stock options aligns the interests of Executive VP-Administration and Director Steven D. Rubin with those of shareholders, incentivizing long-term company performance.
• The options provide a potential future value for the executive, contingent on the company's stock price appreciation above the exercise price.

Negatives

• No immediate negative implications are apparent from this routine executive compensation grant.

Risks

• The value of the stock options is subject to the future market price of OPKO Health's common stock; if the stock price does not exceed the exercise price of $1.31, the options may expire worthless.
• The options are subject to a vesting schedule, meaning the executive must remain employed with the company for the specified periods to fully realize the grant.

Future Outlook

The vesting schedule of the stock options, extending through May 2029, indicates a long-term incentive structure designed to align the executive's future performance with shareholder value creation.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries as a form of executive compensation, aiming to attract, retain, and motivate key personnel by linking their financial incentives to the company's long-term stock performance.

Related Party Transactions

• This document details an equity compensation grant to Steven D. Rubin, an executive officer and director, which is a transaction between the company and a related party (insider).

Stakeholder Impact

• Shareholders: The grant aims to align the executive's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: While specific to one executive, such compensation practices can influence overall employee morale and retention strategies.

Next Steps

• The stock options will begin to vest in four equal annual installments starting May 27, 2026.

Key Dates

Keywords

OPKO Health, OPK, Stock Options, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Steven D. Rubin